Drug Profile
Research programme: siRNA delivery therapeutics - siRNAx
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator siRNAx
- Class Recombinant fusion proteins; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Waldenstrom's macroglobulinaemia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Waldenstrom's macroglobulinaemia in USA (Parenteral)
- 11 Aug 2016 Early research in Waldenstrom's macroglobulinaemia in USA (Parenteral)